Compare RNW & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | FTRE |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2021 | 2023 |
| Metric | RNW | FTRE |
|---|---|---|
| Price | $6.96 | $19.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $7.78 | ★ $23.63 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $18.42 | N/A |
| Revenue Next Year | $18.46 | $3.21 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $4.39 | $8.55 |
| 52 Week High | $7.69 | $26.16 |
| Indicator | RNW | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 66.73 | 41.42 |
| Support Level | $6.83 | $19.36 |
| Resistance Level | N/A | $21.25 |
| Average True Range (ATR) | 0.03 | 1.44 |
| MACD | 0.00 | -0.35 |
| Stochastic Oscillator | 88.89 | 15.15 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.